<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2003-9-5-160-163</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-888</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Влияние терапии бисопрололом на перфузию головного мозга у больных с метаболическим синдромом</article-title><trans-title-group xml:lang="en"><trans-title>Inpact of bisoprolol therapy on brain perfusion in patients with metabolic syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мычка</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Mychka</surname><given-names>V. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сергиенко</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Sergienko</surname><given-names>V. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горностаев</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gornostaev</surname><given-names>V. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Двоскина</surname><given-names>И. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Dvoskina</surname><given-names>I. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чазова</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Chazova</surname><given-names>I. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Институт клинической кардиологии им. А.Л. Мясникова<country>Россия</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Институт клинической кардиологии им. А.Л. Мясникова; Российский кардиологический научно-производственный комплекс Минздрава РФ<country>Россия</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2003</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2003</year></pub-date><volume>9</volume><issue>5</issue><fpage>160</fpage><lpage>163</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мычка В.Б., Сергиенко В.Б., Горностаев В.В., Двоскина И.М., Чазова И.Е., 2003</copyright-statement><copyright-year>2003</copyright-year><copyright-holder xml:lang="ru">Мычка В.Б., Сергиенко В.Б., Горностаев В.В., Двоскина И.М., Чазова И.Е.</copyright-holder><copyright-holder xml:lang="en">Mychka V.B., Sergienko V.B., Gornostaev V.V., Dvoskina I.M., Chazova I.E.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/888">https://htn.almazovcentre.ru/jour/article/view/888</self-uri><abstract><p>Основной причиной смерти при метаболическом синдроме являются сердечно-сосудистые осложнения в связи с высокой частотой поражения органов-мишеней. Для лечения пациентов с метаболическим синдромом необходим более тщательный подбор лекарственного препарата или их сочетание с целью избежать неблагоприятных метаболических эффектов и вместе с тем адекватно контролировать артериальное давление. Долгое время считалось, что β-блокатры оказывают отрицательное действие на липидный и углеводный обмен, а также способны ухудшать перфузию головного мозга у пациентов с артериальной гипертонией. Цель данной работы — изучение влияния бисопролола на суточный профиль АД, метаболизм липидов и углеводов, а также на перфузию головного мозга у пациентов с метаболическим синдромом и артериальной гипертонией.</p></abstract><trans-abstract xml:lang="en"><p>In the metabolic syndrome, the main cause of death is cardiovascular events due to the high rate of damage to target organs, lb treat patients with the metabolic syndrome, it is necessary to more thoroughly choose drugs or their combination to prevent adverse metabolic effects and at the same time to adequately monitor blood pressure. It has been long considered that β-blockers exert a negative effect on lipid and carbohydrate metabolism and they arc able to deteriorate brain perfusion in patients with arterial hypertension. This study was undertaken to evaluate the effects of bisoprolol on the daily BP profile, lipid and carbohydrate metabolism and brain perfusion in patients with the metabolic syndrome and hypertension.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>метаболический синдром</kwd><kwd>бисопролол</kwd><kwd>углеводный обмен</kwd><kwd>липидный обмен</kwd><kwd>перфузия головного мозга</kwd><kwd>однофотонная эмиссионная компьютерная томография</kwd></kwd-group><kwd-group xml:lang="en"><kwd>β-адреноблокатры</kwd><kwd>hypertension</kwd><kwd>metabolic syndrome</kwd><kwd>β-adrenoblockers</kwd><kwd>bisoprolol</kwd><kwd>carbohydrate metabolism</kwd><kwd>lipid metabolism: brain perfusion</kwd><kwd>single-photon emission computed tomography</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bertel O., Marx B.E., Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med. 1987 Mar 30;82 (3B): 29-36.</mixed-citation><mixed-citation xml:lang="en">Bertel O., Marx B.E., Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med. 1987 Mar 30;82 (3B): 29-36.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer J.S., Rogers R.L., Mortel K.F. Prospective analysis of long term control of mild hypertension on cerebral blood flow. Stroke. 1985 Nov-Dec; 16 (6): 985-90.</mixed-citation><mixed-citation xml:lang="en">Meyer J.S., Rogers R.L., Mortel K.F. Prospective analysis of long term control of mild hypertension on cerebral blood flow. Stroke. 1985 Nov-Dec; 16 (6): 985-90.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hares P., James I.M., Griffith D. The effect of acebutolol on the cerebral circulation of man. Br J Clin Pharmacol. 1977 Jun; 4 (3): 373-5.</mixed-citation><mixed-citation xml:lang="en">Hares P., James I.M., Griffith D. The effect of acebutolol on the cerebral circulation of man. Br J Clin Pharmacol. 1977 Jun; 4 (3): 373-5.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fuijshima M., Ihayashi S., Fugii K. et al. Effects of lonf-term antihypertensive treatment on cerebral thalamic and cerebral blood flow in spontaneously hypertensive rats SHR. Stroke 1986; 17-5.</mixed-citation><mixed-citation xml:lang="en">Fuijshima M., Ihayashi S., Fugii K. et al. Effects of lonf-term antihypertensive treatment on cerebral thalamic and cerebral blood flow in spontaneously hypertensive rats SHR. Stroke 1986; 17-5.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fogari R., Zoppi A., Corradi L., Preti P., Mugellini A., Lusardi P. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 1999 Apr; 33 (4): 534-9.</mixed-citation><mixed-citation xml:lang="en">Fogari R., Zoppi A., Corradi L., Preti P., Mugellini A., Lusardi P. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 1999 Apr; 33 (4): 534-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Vulpis V., Antonacci A., Prandi P., Bokor D., Pirrelli A. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Minerva Med. 1991 Apr; 82 (4): 189-93.</mixed-citation><mixed-citation xml:lang="en">Vulpis V., Antonacci A., Prandi P., Bokor D., Pirrelli A. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Minerva Med. 1991 Apr; 82 (4): 189-93.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Frithz G. Influence on plasma-insulin and blood-glucose by treatment with disoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001; 4: 229-30.</mixed-citation><mixed-citation xml:lang="en">Frithz G. Influence on plasma-insulin and blood-glucose by treatment with disoprolol in hypertensive, non-diabetic patients. J Clin Basic Cardiol 2001; 4: 229-30.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fogari R., Zoppi A., Tettamanti F., Poletti L., Lazzari P., Pasotti C., Corradi L. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol. 1990; 16 Suppl 5: S76-80.</mixed-citation><mixed-citation xml:lang="en">Fogari R., Zoppi A., Tettamanti F., Poletti L., Lazzari P., Pasotti C., Corradi L. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol. 1990; 16 Suppl 5: S76-80.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chang P.C., van Veen S., Vermeij P., van Brummelen P. Double-blind comparison of the beta 1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol. 1986; 8 Suppl 11: S58-60.</mixed-citation><mixed-citation xml:lang="en">Chang P.C., van Veen S., Vermeij P., van Brummelen P. Double-blind comparison of the beta 1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol. 1986; 8 Suppl 11: S58-60.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Asmar R.G., Kerihuel J.C., Girerd X.J., Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol. 1991 Jul 1;68 (1): 61-4.</mixed-citation><mixed-citation xml:lang="en">Asmar R.G., Kerihuel J.C., Girerd X.J., Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol. 1991 Jul 1;68 (1): 61-4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Frithz G., Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol. 1987; 32 (1): 77-80.</mixed-citation><mixed-citation xml:lang="en">Frithz G., Weiner L. Effects of bisoprolol on blood pressure, serum lipids and HDL-cholesterol in essential hypertension. Eur J Clin Pharmacol. 1987; 32 (1): 77-80.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Haneda T., Ido A., Fujikane T., Tanaka H., Tanazawa S., Morimoto H., Kato J., Kanaya K., Honda H., Sakai H., Akita N., Hirayama T., Onodera S., Kikuchi K. Effect of bisoprolol, a beta 1-selective beta-blocker, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Nihon Ronen Igakkai Zasshi. 1998 Jan; 35 (1): 33-8.</mixed-citation><mixed-citation xml:lang="en">Haneda T., Ido A., Fujikane T., Tanaka H., Tanazawa S., Morimoto H., Kato J., Kanaya K., Honda H., Sakai H., Akita N., Hirayama T., Onodera S., Kikuchi K. Effect of bisoprolol, a beta 1-selective beta-blocker, on lipid and glucose metabolism and quality of life in elderly patients with essential hypertension. Nihon Ronen Igakkai Zasshi. 1998 Jan; 35 (1): 33-8.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol. 1986; 8 Suppl 11: S96-9.</mixed-citation><mixed-citation xml:lang="en">Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol. 1986; 8 Suppl 11: S96-9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Dominguex L.J., Barbagallo M., Jacoher S.J., Jacobs D.B., Sowers J.R. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens. 1997 Dec;10 (12 Pt 1): 1349-55.</mixed-citation><mixed-citation xml:lang="en">Dominguex L.J., Barbagallo M., Jacoher S.J., Jacobs D.B., Sowers J.R. Bisoprolol and captopril effects on insulin receptor tyrosine kinase activity in essential hypertension. Am J Hypertens. 1997 Dec;10 (12 Pt 1): 1349-55.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Верещагин Н.В., Борисенко В.В., Власенко В.В. Мозговое кровообращение. Современные методы исследования в клинической неврологии.</mixed-citation><mixed-citation xml:lang="en">Верещагин Н.В., Борисенко В.В., Власенко В.В. Мозговое кровообращение. Современные методы исследования в клинической неврологии.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998 Sep 12; 317 (7160): 713-20.</mixed-citation><mixed-citation xml:lang="en">UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998 Sep 12; 317 (7160): 713-20.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
